Superconducting transition of a two-dimensional Josephson junction array in weak magnetic fields

The superconducting transition of a two-dimensional (2D) Josephson junction array exposed to weak magnetic fields has been studied experimentally. Resistance measurements reveal a superconducting-resistive phase boundary in serious disagreement with the theoretical and numerical expectations. Critical scaling analyses of the $IV$ characteristics indicate contrary to the expectations that the superconducting-to-resistive transition in weak magnetic fields is associated with a melting transition of magnetic-field-induced vortices directly from a pinned-solid phase to a liquid phase. The expected depinning transition of vortices from a pinned-solid phase to an intermediate floating-solid phase was not observed. We discuss effects of the disorder-induced random pinning potential on phase transitions of vortices in a 2D Josephson junction array.Comment: 9 pages, 7 figures (EPS+JPG format), RevTeX

Superconducting phase transitions in frustrated Josephson-junction arrays on a dice lattice

Transport measurements are carried out on dice Josephson-junction arrays with the frustration index $f=1/3$ and 1/2 which possess, within the limit of the $XY$ model, an accidental degeneracy of the ground states as a consequence of the formation of zero-energy domain walls. The measurements demonstrate that both the systems undergo a phase transition to a superconducting vortex-ordered state at considerably high temperatures. The experimental findings are in apparent contradiction with the theoretical expectation that frustration effects in the $f=1/3$ system are particularly strong enough to suppress a vortex-ordering transition down to near zero temperature. The data for $f=1/2$ are more consistent with theoretical evaluations. The agreement between the experiments and the Monte Carlo simulations of a $XY$ model for $f=1/3$ suggests that the order-from-disorder mechanism for the removal of an accidental degeneracy may still be effective in the $f=1/3$ system. The transport data also reveal that the dice arrays with zero-energy domain walls experience a much slower critical relaxation than other frustrated arrays only with finite-energy walls.Comment: 4 pages, 4 figure

Direct observation of a liquid film under a vapor environment in a pool boiling using a nanofluid

The existence of a liquid film separating a vapor bubble from a heated solid surface is confirmed using a nanofluid. The existence of such a liquid film had been a theoretical premise of the critical heat flux mechanism, significantly difficult to verify through experimental observations. Here, we show that a liquid film under a massive vapor bubble adheres to a heated solid surface. The liquid film comes into being trapped in a dynamic coalescence environment of nucleate bubbles, which grow and depart continuously from the heated surface. In its dryout process, the liquid film displays vapor "holes" originating from the rupture of discrete nucleating bubbles. The dryout process of the liquid film can be understood from the vaporization of rims of the holes and of smooth film region.open51

Critical Behavior of Frustrated Josephson Junction Arrays with Bond Disorder

The scaling behavior of the current-voltage ($IV$) characteristics of a two-dimensional proximity-coupled Josephson junction array (JJA) with quenched bond disorder was investigated for frustrations $f=1/5$, 1/3, 2/5, and 1/2. For all these frustrations including 1/5 and 2/5 where a strongly first-order phase transition is expected in the absence of disorder, the $IV$ characteristics exhibited a good scaling behavior. The critical exponent $\nu$ indicates that bond disorder may drive the phase transitions of frustrated JJA's to be continuous but not into the Ising universality class, contrary to what was observed in Monte Carlo simulations. The dynamic critical exponent $z$ for JJA's was found to be only 0.60 - 0.77.Comment: RevTeX4, 4 pages, 4 figures, the manuscript is replaced with the published versio

Frustrated two-dimensional Josephson junction array near incommensurability

To study the properties of frustrated two-dimensional Josephson junction arrays near incommensurability, we examine the current-voltage characteristics of a square proximity-coupled Josephson junction array at a sequence of frustrations f=3/8, 8/21, 0.382 $(\approx (3-\sqrt{5})/2)$, 2/5, and 5/12. Detailed scaling analyses of the current-voltage characteristics reveal approximately universal scaling behaviors for f=3/8, 8/21, 0.382, and 2/5. The approximately universal scaling behaviors and high superconducting transition temperatures indicate that both the nature of the superconducting transition and the vortex configuration near the transition at the high-order rational frustrations f=3/8, 8/21, and 0.382 are similar to those at the nearby simple frustration f=2/5. This finding suggests that the behaviors of Josephson junction arrays in the wide range of frustrations might be understood from those of a few simple rational frustrations.Comment: RevTex4, 4 pages, 4 eps figures, to appear in Phys. Rev.

P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.Background Because anaplastic lymphoma kinase (ALK) is dependent on Hsp90 for protein stability, Hsp90 inhibitors are effective in controlling growth of lung cancer cells with ALK rearrangement. We investigated the mechanism of acquired resistance to 17-(Dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), a geldanamycin analogue Hsp90 inhibitor, in H3122 and H2228 non-small cell lung cancer cell lines with ALK rearrangement. Methods Resistant cell lines (H3122/DR-1, H3122/DR-2 and H2228/DR) were established by repeated exposure to increasing concentrations of 17-DMAG. Mechanisms for resistance by either NAD(P)H/quinone oxidoreductase 1 (NQO1), previously known as a factor related to 17-DMAG resistance, or P-glycoprotein (P-gp; ABCB1/MDR1) were queried using RT-PCR, western blot analysis, chemical inhibitors, the MTT cell proliferation/survival assay, and cellular efflux of rhodamine 123. Results The resistant cells showed no cross-resistance to AUY922 or ALK inhibitors, suggesting that ALK dependency persists in cells with acquired resistance to 17-DMAG. Although expression of NQO1 was decreased in H3122/DR-1 and H3122/DR-2, NQO1 inhibition by dicumarol did not affect the response of parental cells (H2228 and H3122) to 17-DMAG. Interestingly, all resistant cells showed the induction of P-gp at the protein and RNA levels, which was associated with an increased efflux of the P-gp substrate rhodamine 123 (Rho123). Transfection with siRNA directed against P-gp or treatment with verapamil, an inhibitor of P-gp, restored the sensitivity to the drug in all cells with acquired resistance to 17-DMAG. Furthermore, we also observed that the growth-inhibitory effect of 17-DMAG was decreased in A549/PR and H460/PR cells generated to over-express P-gp by long-term exposure to paclitaxel, and these cells recovered their sensitivity to 17-DMAG through the inhibition of P-gp. Conclusion P-gp over-expression is a possible mechanism of acquired resistance to 17-DMAG in cells with ALK rearrangement

Comprehensive analysis of mycobacterium tuberculosis antigen-specific CD4+ T cell responses restricted by single HLA class II allotype in an individual

Mycobacterium tuberculosis infection is generally asymptomatic as latent tuberculosis, but it is still known as the world’s leading bacterial cause of death. The diagnosis of latent tuberculosis infection relies on the evidence of cellular immunity to mycobacterial antigens. Since the association between HLA class II and tuberculosis infection has been reported in several population groups, a detailed study on the CD4+ T cell response to major tuberculosis antigens is needed. To elucidate which HLA class II allotypes in an individual are preferentially used in tuberculosis, CD4+ T cells specific to TB10.4, Ag85b, ESAT-6, and CFP-10 of Mycobacterium tuberculosis antigens were analyzed comprehensively. A total of 33 healthy donors were analyzed by ex vivo and cultured ELISPOT using panels of artificial antigen-presenting cells expressing a single HLA class II allotype. The CD4+ T cell responses were increased by an average of 39-fold in cultured ELISPOT compared with ex vivo ELISPOT. In ex vivo and cultured ELISPOT, CD4+ T cell responses showed significantly higher by HLA-DR than those of HLA-DQ and HLA-DP locus. In cultured ELISPOT, 9 HLA-DR allotypes, 4 HLA-DQ allotypes, and 3 HLA-DP allotypes showed positive CD4+ T cell responses. Among ten donors with positive CD4+ T cell responses when tested for mixed Mycobacterium tuberculosis antigens, seven donors were positive for only a single allotype, and three were positive for two allotypes in an individual. However, only one allotype was used for a single antigen-specific response when a single tuberculosis antigen was used individually. These results on the distribution of HLA class II allotypes showing high CD4+ T-cell responses to Mycobacterium tuberculosis antigens and the intra-individual allotype dominance will provide valuable information for understanding the immunobiology and immunogenetics of tuberculosis, which can contribute to the development of more effective vaccines

Gene expression profile of the skin in the 'hairpoor' (HrHp) mice by microarray analysis

<p>Abstract</p> <p>Background</p> <p>The transcriptional cofactor, Hairless (HR), acts as one of the key regulators of hair follicle cycling; the loss of function mutations is the cause of the expression of the hairless phenotype in humans and mice. Recently, we reported a new <it>Hr </it>mutant mouse called 'Hairpoor' (<it>Hr^Hp</it>). These mutants harbor a gain of the function mutation, T403A, in the <it>Hr </it>gene. This confers the overexpression of HR and <it>Hr^Hp</it>is an animal model of Marie Unna hereditary hypotrichosis in humans. In the present study, the expression profile of <it>Hr^Hp/Hr^Hp</it>skin was investigated using microarray analysis to identify genes whose expression was affected by the overexpression of HR.</p> <p>Results</p> <p>From 45,282 mouse probes, differential expressions in 43 (>2-fold), 306 (>1.5-fold), and 1861 genes (>1.2-fold) in skin from <it>Hr^Hp/Hr^Hp</it>mice were discovered and compared with skin from wild-type mice. Among the 1861 genes with a > 1.2-fold increase in expression, further analysis showed that the expression of eight genes known to have a close relationship with hair follicle development, ascertained by conducting real-time PCR on skin RNA produced during hair follicle morphogenesis (P0-P14), indicated that four genes, <it>Wif1</it>, <it>Casp14</it>, <it>Krt71</it>, and <it>Sfrp1</it>, showed a consistent expression pattern with respect to HR overexpression in vivo.</p> <p>Conclusion</p> <p><it>Wif1 </it>and <it>Casp14 </it>were found to be upregulated, whereas <it>Krt71 </it>and <it>Sfrp1 </it>were downregulated in cells overexpressing HR in transient transfection experiments on keratinocytes, suggesting that HR may transcriptionally regulate these genes. Further studies are required to understand the mechanism of this regulation by the HR cofactor.</p

Long-term efficacy, safety and immunogenicity in patients with rheumatoid arthritis continuing on an etanercept biosimilar (LBEC0101) or switching from reference etanercept to LBEC0101: an open-label extension of a phase III multicentre, randomised, double-blind, parallel-group study

Background To evaluate the long-term efficacy, safety and immunogenicity of continuing LBEC0101; the etanercept (ETN) biosimilar; or switching from the ETN reference product (RP) to LBEC0101 in patients with rheumatoid arthritis (RA). Methods This multicentre, single-arm, open-label extension study enrolled patients who had completed a 52-week randomised, double-blind, parallel phase III trial of LBEC0101 vs ETN-RP. Patients treated with ETN-RP during the randomised controlled trial switched to LBEC0101; those treated with LBEC0101 continued to receive LBEC0101 in this study. LBEC0101 (50 mg) was administered subcutaneously once per week for 48 weeks with a stable dose of methotrexate. Efficacy, safety and immunogenicity of LBEC0101 were assessed up to week 100. Results A total of 148 patients entered this extension study (70 in the maintenance group and 78 in the switch group). The 28-joint disease activity scores (DAS28)-erythrocyte sedimentation rate (ESR) were maintained in both groups from week 52 to week 100 (from 3.068 to 3.103 in the maintenance group vs. from 3.161 to 3.079 in the switch group). ACR response rates at week 100 for the maintenance vs. switch groups were 79.7% vs. 83.3% for ACR20, 65.2% vs. 66.7% for ACR50 and 44.9% vs. 42.3% for ACR70. The incidence of adverse events and the proportion of patients with newly developed antidrug antibodies were similar in the maintenance and switch groups (70.0% and 70.5%, 1.4% and 1.3%, respectively). Conclusions Administration of LBEC0101 showed sustained efficacy and acceptable safety in patients with RA after continued therapy or after switching from ETN-RP to LBEC0101. Trial registration ClinicalTrials.gov, NCT02715908. Registered 22 March 2016.This extension study was funded by LG Chem, Ltd. (formerly, LG Life Sciences, Ltd), Mochida Pharmaceutical Co., Ltd. and Korea Health Industry Development Institute